Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.49 |
| ▸ | AR | P10275 | 5/20 | 0.48 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29257436 | 0.92 | CRBN (0.51) | CRBNDDB1ARPRMT5WDR77 | |
| SCHEMBL29614689 | 0.92 | CRBN (0.51) | CRBNDDB1ARPRMT5WDR77 | |
| SCHEMBL22291386 | 0.92 | CRBN (0.51) | CRBNDDB1 | |
| SCHEMBL29617074 | 0.92 | CRBN (0.51) | CRBNDDB1 | |
| SCHEMBL22291670 | 0.88 | ALK (0.38) | CRBNDDB1ARPRMT5WDR77 | |
| SCHEMBL30696651 | 0.88 | CRBN (0.48) | CRBNDDB1ARPRMT5WDR77 | |
| SCHEMBL23249925 | 0.87 | CRBN (0.49) | CRBNDDB1ARPRMT5WDR77 | |
| SCHEMBL29874161 | 0.87 | CRBN (0.49) | CRBNDDB1ARPRMT5WDR77 | |
| SCHEMBL22291575 | 0.87 | CRBN (0.38) | CRBNDDB1AR | |
| SCHEMBL31560072 | 0.86 | CRBN (0.55) | CRBNDDB1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391686-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-03-16 | — | — | US | disclosed |
| EP-3917526-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 56/4885DDB1 699/4885AR 2465/4885 |
| US-12391686-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | CRBN 56/4885DDB1 699/4885AR 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.